Skip Navigation


Annals of Oncology Advance Access originally published online on May 25, 2008
Annals of Oncology 2008 19(8):1369-1370; doi:10.1093/annonc/mdn373
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/8/1369    most recent
mdn373v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Négrier, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Négrier, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorials

Temsirolimus in metastatic renal cell carcinoma

S. Négrier*

Centre Léon Bérard, Medical Oncology, 28 Rue Laennec, 69008 Lyon, France

* E-mail: negrier@lyon.fnclcc.fr

The first 10% of the full text of this article appears below.

Metastatic renal cell carcinoma was considered for decades a hopeless cancer, with only limited treatment options. The recent development of what is generally referred to as ‘targeted molecules’ opened new treatment options and substantially improved the prognosis of patients suffering from this disease. The carcinogenesis of the main histologic subtype of renal tumours, the clear cell type, is dominated by the vascular endothelial growth factor (VEGF) dependence of tumour cell growth [1]. Indeed, the mutation or impairment of the VEGF gene that is commonly observed in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?